Recent Articles:
BioPartnering North America: Strength in Partnerships
As a plethora of industries face a combination of economic pressures, and low returns on internal research and development, managers in the Biotechnology and Pharma industries are creating new strategies and new approaches.
Technologies Launched at BPN 2012
The University of Manitoba Technology Transfer Office has participated at BioPartnering North America for the past five years. This year, we are "launching" some of our newest technologies at this highly anticipated event.
The professionals at the University of Manitoba's Technology Transfer Office are the reason we are one of Canada's most productive intellectual asset programs.
DiaMedica Named One of TSX Venture's Top 50 Companies
DiaMedica Inc. has been named as one of the TSX Venture Top 50 companies for 2012, an annual ranking of Canada's emerging publicly traded companies.
Opportunities in Antibodies: From Research Tools to Biologic Therapeutics
Since their Nobel-prize winning discovery 1974 by Kohler and Milstein, monoclonal antibodies quickly realized their promise as useful research tools and reagents, leading to a nearly logarithmic increase in citing publications within a few years. The first monoclonal antibody-based clinical therapeutic was approved by the FDA in 1986, and the development of monoclonal antibody based drugs really took off as technical challenges were met in the 1990s. University of Manitoba biomedical researchers have been involved in this story right from the beginning. The University of Manitoba Technology Transfer Office (TTO) provides intellectual property and commercialization support for Manitoban monoclonals as research tools, diagnostics and potential therapeutics.
Diabetic Sensory Neuropathy
Diabetes is rising at an alarming rate, and with diabetes comes a greater risk of developing neurological diseases such as peripheral neuropathy (nerve dysfunction) and Alzheimer's disease. Approximately 50 percent of all people with diabetes - both type 1 and type 2 - will experience some form of peripheral neuropathy. In North America alone, over the next 5 years, as many as 10 million people are expected to develop this disease. And, there is currently no effective therapy.
Patents and Putters
Drive. Slice. Hook 'em. That was the motto on golfers minds as they headed to the Winnipeg's Tuxedo Golf Club for the first ever Patents & Putters Golf Tournament. The players were graced with gorgeous fall - albeit windy - weather as they teed off in hopes of earning the rights to call themselves this year's golf champ.
